Khiron Announces Grants of Options and Restricted Share Units

TORONTO, Nov. 23, 2021 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the award of stock options ("Options") and restricted share units ("RSUs") under the Company's amended and restated restricted share unit plans approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020.

On November 23, 2021, the board of directors granted a total of 1,400,000 Options and 950,000 RSUs to certain officers of the Company. Certain of the Options and RSUs are subject to performance-based vesting conditions. The Options are exercisable at a price of $0.75 per share and will expire on November 23, 2026. Unvested RSUs will expire on December 15, 2024.

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated international medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.

Visit Khiron online at investors.khiron.ca  and on Linkedin at
https://www.linkedin.com/company/khiron-life-sciences-corp/

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Investor Contact:
Paola Ricardo
E: [email protected]
T: [phone]

Media Contact:
Peter Leis
Europe Communications
E: [email protected]

Carolina Gomez
Latam Communications
E: [email protected]

Khiron Europe:
Franziska Katterbach, President
E: [email protected]

SOURCE Khiron Life Sciences Corp.

Investor Contact: Paola Ricardo, E: [email protected], T: [phone]; Media Contact: Peter Leis, Europe Communications, E: [email protected]; Carolina Gomez, Latam Communications, E: [email protected]; Khiron Europe: Franziska Katterbach, President, E: [email protected]